Metformin Therapy for Patients With COVID-19 Without Obesity—Reply

In Reply In response to the thoughtful comments by Chang and Jean, we acknowledge that there are limitations related to the design of the ACTIV-6 trial, most of which are noted in the primary publication. We appreciate the opportunity to respond further to these points below.

from JAMA Internal Medicine Online First https://ift.tt/Cgb2YsM